IMNM Immunome, Inc.
$24.67▼ -1.20%
Healthcare
Other
After hours
$24.67▲ +0.00%
Sep 11, 7:30 PM ET
Volume 692.6K
Avg Volume (10D) 810.2K
Key Metrics & Fundamentals
Market Cap
$2.80B
P/E Ratio
–
Div Yield
–%
52W Range
8.93 - 30.06
% vs 50 MA
-2.36%
% vs 200 MA
9.76%
RSI-14
39.3
MACD Histogram
-0.5500
Beta (1Y vs SPY)
1.69
Free Cash Flow
-$63.87M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$76.97M
COGS
–
Operating Exp
$78.14M
Operating Income
-$78.14M
EBIT
-$78.14M
Pretax Income
-$73.13M
Net Income
-$73.13M
EPS (Diluted)
-0.65
Price & Volume History
Loading chart…
Recent News
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Sep 8, 2026 8:02 PM
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 2, 2026 11:45 AM
Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating
MT Newswires · Aug 12, 2026 11:10 AM
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 11, 2026 8:02 PM
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Business Wire · Jul 20, 2026 11:30 AM
What This Immunome Sale Means a Day Before a Big FDA Milestone
Motley Fool · Jul 12, 2026 9:04 PM
Immunome Stock Up 32% in a Month: Here's What You Should Know
Zacks · Jul 10, 2026 2:40 PM
Immunome Says FDA Accepted NDA for Desmoid Tumors Drug
MT Newswires · Jul 8, 2026 12:06 PM
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Business Wire · Jul 8, 2026 11:30 AM
Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing
MT Newswires · Jul 8, 2026 7:34 AM
Financial Overview - Income Statement
Quarterly
Jun 2025
See IMNM's money flow as a full page
Social Sentiment
No Reddit posts found for IMNM.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.